A biotechnology company that engineers gene therapies for rare, severe neurological diseases, mostly affecting children, such as Rett syndrome. Its EXACT technology acts like a built-in dial, fine-tuning how much of a therapeutic protein a cell makes to avoid the toxicity that often plagues conventional gene therapy. The company was founded in 2018 by Rachel McMinn, a biotech analyst whose older brother lives with an undiagnosed neurological condition—the personal spark behind the whole venture—and it went public in 2023 through a reverse merger.
Smith Sean MichaelInterim CFO, Prin Acct Off · 6 transactions
—
21.6Kas of Aug 2023
22.5K
—
6.3K
Jordan JulieChief Medical Officer · 3 transactions
—
12.5K
13.3K
—
828
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +2.33M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.